跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
醫學系精神學科
醫學院
醫學系
概覽
指紋
網路
人員
(4)
研究成果
(666)
指紋
查看啟用 醫學系精神學科 的研究主題。這些主題標籤來自此機構會員的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Bipolar Disorder
100%
Major Depressive Disorder
88%
Taiwan
80%
Confidence Interval
74%
Treatment-resistant Depression
70%
National Cohort Study
68%
Schizophrenia
67%
Attention Deficit Hyperactivity Disorder
60%
Hazard Ratio
57%
Autism Spectrum Disorder
42%
Antidepressants
41%
Schizophrenic Patients
39%
Ketamine
36%
Low-dose Ketamine Infusion
34%
Patients with Schizophrenia
33%
Antipsychotics
30%
Older Adults
27%
Odds Ratio
27%
Major Psychiatric Disorders
27%
Inflammatory Cytokines
23%
High Risk
23%
Taiwanese
22%
Comorbidity
22%
Suicide
21%
Taiwan National Health Insurance Research Database
20%
Tardive Dyskinesia
19%
Clozapine
19%
Suicidal Ideation
19%
Cognitive Function
19%
Obsessive-compulsive Disorder
18%
Depressive Disorder
18%
Ketamine Infusion
17%
First-degree Relatives
16%
Psychiatric Comorbidity
16%
Atypical Antipsychotics
15%
Dementia Risk
15%
Unaffected Siblings
15%
Dementia
15%
Antisuicidal Effect
15%
Nested Case-control Study
15%
Longitudinal Follow-up
14%
Bidirectional Association
14%
Polymorphism
14%
Suicide Risk
14%
Alzheimer's Disease
14%
Population-based
14%
Substance Use Disorder
13%
Depressive Symptoms
12%
Intermittent theta Burst Stimulation (iTBS)
12%
Healthy Controls
12%
Functional Connectivity
12%
Anxiety Disorders
12%
Repetitive Transcranial Magnetic Stimulation (rTMS)
12%
Suicide Attempt
11%
Posttraumatic Stress Disorder
11%
Bipolar I Disorder
11%
Population-based Cohort Study
11%
Metabolic Syndrome
11%
Proband
11%
Asthma
11%
Atopic Dermatitis
10%
Parkinson's Disease
10%
Randomized Double-blind
10%
Psychiatric Disorders
10%
Treatment Response
10%
Sham Control
10%
National Health Insurance Research Database (NHIRD)
10%
Later Life
10%
Stroke Risk
10%
Body Mass Index
9%
Familial Coaggregation
9%
Adjusted Hazard Ratio
9%
Alopecia Areata
9%
Risperidone
9%
Tumor Necrosis Factor-α
9%
Low-dose Ketamine
9%
TNF Receptor 1 (TNFR1)
8%
Weight Gain
8%
Risk Factors
8%
Unipolar Depression
8%
Placebo
8%
Bipolar Disorder Depression
8%
Second-generation Antipsychotics
8%
Sexually Transmitted Infections
8%
Relative Risk
8%
Mood Disorders
8%
Prefrontal Cortex
7%
Proton Pump Inhibitors
7%
Severe Mental Illness
7%
Pathophysiology
7%
Affective Disorders
7%
Psychiatric Patients
7%
Comorbid
7%
Demographic Data
7%
Rapid-acting Antidepressant
7%
Cumulative Defined Daily Dose
7%
Alcohol Use Disorder
7%
All-cause Mortality
7%
Type 1 Diabetes Mellitus (T1DM)
7%
ICD-9
7%
Neuroscience
Bipolar Disorder
85%
Major Depressive Disorder
83%
Longitudinal Study
64%
Treatment-Resistant Depression
56%
Antidepressant
52%
Ketamine
47%
Mental Disorder
45%
Attention Deficit Hyperactivity Disorder
43%
Comorbidity
37%
Pervasive Developmental Disorder
31%
Depressive Disorder
22%
Proinflammatory Cytokine
20%
Tardive Dyskinesia
20%
Clozapine
17%
Atypical Antipsychotic
16%
Functional Connectivity
16%
Cognitive Function
15%
Transcranial Magnetic Stimulation
15%
Obsessive-Compulsive Disorder
14%
Cerebrovascular Accident
13%
Placebo
13%
Prefrontal Cortex
12%
Alzheimer's Disease
11%
Bipolar I Disorder
11%
Antipsychotic
11%
Cognitive Disorders
11%
Mood Disorder
10%
Anxiety Disorder
9%
Parkinson's Disease
9%
Brain-Derived Neurotrophic Factor
9%
Posttraumatic Stress Disorder
8%
Single-Nucleotide Polymorphism
8%
Diabetes Mellitus
8%
Negative Syndrome
8%
Positive Syndrome
8%
Body Mass Index
7%
Risperidone
7%
C-Reactive Protein
7%
Executive Function
7%
Olanzapine
7%
Necrosis
6%
Migraine
6%
Bipolar II Disorder
6%
Schizophrenia
6%
Gray Matter Volume
6%
Autism
6%
Genetic Variation
6%
Tumor Necrosis Factor Receptor 1
6%
Hamilton Rating Scale for Depression
6%
Neurotrauma
6%
Traumatic Brain Injury
6%
Executive Dysfunction
5%
Panic Disorder
5%
Brain Ischemia
5%
Functional Magnetic Resonance Imaging
5%
Somatics
5%
Substance Abuse
5%
Behavior (Neuroscience)
5%
Anterior Cingulate Cortex
5%
Receptor Gene
5%
Magnetic Resonance Imaging
5%
Metabolic Pathway
5%
Dorsolateral Prefrontal Cortex
5%